Supplementary Materials and Methods from CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
posted on 2023-03-31, 00:44authored byTriparna Sen, Pan Tong, C. Allison Stewart, Sandra Cristea, Aly Valliani, David S. Shames, Abena B. Redwood, You Hong Fan, Lerong Li, Bonnie S. Glisson, John D. Minna, Julien Sage, Don L. Gibbons, Helen Piwnica-Worms, John V. Heymach, Jing Wang, Lauren Averett Byers
This file contains additional details of materials and methods used in this study like SCLC cell line authentication, targeted knockdown of CHK1 and MYC, PCR, cell viability aasay, cell cycle analysis, generation of tumor models, RPPA and immunofluorescence.
Funding
NIH
University of Texas MD Anderson Cancer Center Small Cell Lung Cancer Working Group and Abell Hangar Foundation Distinguished Professor Endowment
Sidney Kimmel Scholar Award
Free to Breathe
North Carolina Lung Cancer Partnership
LUNGevity Foundation
Uniting Against Lung Cancer
Jeanne F. Shelby Scholarship Fund
MD Anderson Physician Scientist Award
National Cancer Institute Cancer Clinical Investigator Team Leadership Award